Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)
ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the adva...